Organon Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Organon şirketinin kazançları yıllık ortalama -29.7% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 5.2% oranında azalan oldu. Gelirler yıllık ortalama 2.4% oranında azalan oldu. Organon şirketinin öz sermaye getirisi 263.9% olup, net marjı 20.3% dir.

Anahtar bilgiler

-29.7%

Kazanç büyüme oranı

-30.0%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	14.1%
Gelir büyüme oranı	-2.4%
Özkaynak getirisi	263.9%
Net Marj	20.3%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Organon nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

LSE:0A9W Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	6,409	1,301	1,757	473
30 Jun 24	6,346	1,000	1,873	499
31 Mar 24	6,347	1,047	1,887	511
31 Dec 23	6,263	1,023	1,891	528
30 Sep 23	6,150	585	1,892	536
30 Jun 23	6,168	754	1,794	526
31 Mar 23	6,145	746	1,766	504
31 Dec 22	6,174	917	1,702	471
30 Sep 22	6,292	1,011	1,717	439
30 Jun 22	6,355	1,107	1,665	398
31 Mar 22	6,365	1,304	1,658	368
31 Dec 21	6,304	1,351	1,669	339
30 Sep 21	6,314	1,525	1,620	289
30 Jun 21	6,327	1,762	1,553	257
31 Mar 21	6,258	1,917	1,421	232
31 Dec 20	6,532	2,256	1,356	210
31 Dec 19	7,777	3,306	1,443	220
31 Dec 18	9,777	2,153	1,956	365
31 Dec 17	10,500	1,801	2,250	355

Kaliteli Kazançlar: 0A9W yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 0A9W 'nin mevcut net kar marjları (20.3%) geçen yılın (9.5%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 0A9W şirketinin kazançları son 5 yılda yılda 29.7% oranında azaldı.

Büyüme Hızlandırma: 0A9W 'un son bir yıldaki kazanç büyümesi ( 122.4% ) 5 yıllık ortalamasını (yıllık -29.7% ) aşıyor.

Kazançlar vs. Sektör: 0A9W geçen yılki kazanç büyümesi ( 122.4% ) Pharmaceuticals sektörünün 10.2% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 0A9W 'nin Özsermaye Getirisi ( 263.89% ) olağanüstü olsa da, bu ölçüt yüksek borç seviyeleri nedeniyle çarpıktır.

Organon Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

Organon & Co. to Report Q1, 2024 Results on May 02, 2024

Recent updates

Organon & Co. Updates on FDA Review of VTAMA (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Third quarter dividend of US$0.28 announced

Organon & Co. Revises Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings released: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others.

Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion.

Second quarter dividend of US$0.28 announced

Second quarter 2024 earnings released: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Organon & Co. Affirms Revenue Guidance for the Full Year 2024

Investor sentiment deteriorates as stock falls 18%

Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

First quarter dividend of US$0.28 announced

First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

Organon & Co. Provides Earnings Guidance for the Year 2023

Organon & Co., Annual General Meeting, Jun 04, 2024

Organon & Co. to Report Q1, 2024 Results on May 02, 2024

US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary

Fourth quarter dividend of US$0.28 announced

Full year 2023 earnings released: EPS: US$4.01 (vs US$3.61 in FY 2022)

Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024

Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024

Investor sentiment improves as stock rises 21%

Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

Investor sentiment deteriorates as stock falls 17%

Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd)

Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.89 in 3Q 2022)

Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023

Organon & Co.(NYSE:OGN) dropped from FTSE All-World Index (USD)

Organon Announces First Real-World Observational Study of the JADA® System

Organon Announces Two Leadership Appointments

Organon & Co. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.95 (vs US$0.92 in 2Q 2022)

Samsung Bioepis & Organon Announces Topline Results from Interchangeability Study of SB5 Humira Biosimilar

Organon & Co. to Report Q2, 2023 Results on Aug 08, 2023

Organon & Co. & Samsungbioepis Co,.Ltd Announces US Launch of Humira Biosimilar Hadlima (adalimumab-Bwwd) in Multiple Presentations Consistent with Originator

Organon & Co. Declares Guidance Quarterly Dividend, Payable on June 15, 2023

First quarter 2023 earnings released: EPS: US$0.70 (vs US$1.37 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.61 (vs US$5.33 in FY 2021)

Organon Declares Quarterly Dividend, Payable on March 16, 2023

Organon & Co. to Report Q4, 2022 Results on Feb 16, 2023

Organon & Co. Appoints Kirke Weaver as General Counsel and Corporate Secretary, Effective January 1, 2023

Organon Canada Launches Ontruzant®, A Biosimilar of the Reference Biologic Herceptin®, Providing Patients in Canada with Certain Breast and Gastric Cancers with an Additional Therapeutic Option At A Lower Cost

Organon Canada Launches Aybintio Providing New Option at Reduced Cost for Canadians Living with Certain Aggressive Forms of Cancer

Third quarter 2022 earnings released: EPS: US$0.89 (vs US$1.27 in 3Q 2021)

Organon & Co. Revises Earnings Guidance for the Full Year 2022

Organon & Co. to Report Q3, 2022 Results on Nov 03, 2022

Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration Humira® Biosimilar Hadlima™

Second quarter 2022 earnings released: EPS: US$0.92 (vs US$1.70 in 2Q 2021)

Organon & Co. Declares Quarterly Dividend, Payable on September 15, 2022

Organon & Co. to Report Q2, 2022 Results on Aug 04, 2022

Organon & Co. Announces Resignation of Deborah H. Telman as Executive Vice President, General Counsel and Corporate Secretary, Effective July 22, 2022

First quarter 2022 earnings released: EPS: US$1.37 (vs US$1.56 in 1Q 2021)

Organon & Co. Declares Quarterly Dividend, Payable on June 16, 2022

Organon & Co. to Report Q1, 2022 Results on May 05, 2022

Investor sentiment deteriorated over the past week

Organon & Co. Appoints Meghan Rivera as US Managing Director, Organon

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Organon & Co. Provides Earnings Guidance for Full Year 2022

Organon & Co. to Report Q4, 2021 Results on Feb 17, 2022

Samsung Bioepis Co., Ltd. and Organon & Co. announce the U.S. Food and Drug Administration accept for review the supplemental Biologics License Application

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Independent Director recently bought US$101k worth of stock

Organon & Co. Declares Inaugural Quarterly Dividend, Payable on September 13, 2021

Gelir ve Gider Dağılımı